{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:22:45Z","timestamp":1790241765970,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s12325-023-02658-z","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T09:01:46Z","timestamp":1695200506000},"page":"5037-5054","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"Therese","family":"Sargent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Panjabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vienica","family":"Funtanilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley D.","family":"Germack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-595X","authenticated-orcid":false,"given":"Marjolaine","family":"Gauthier-Loiselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameur M.","family":"Manceur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cloutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"2658_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5492","volume":"360","author":"T Thenappan","year":"2018","unstructured":"Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360: j5492.","journal-title":"BMJ"},{"issue":"1","key":"2658_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1378\/chest.10-0075","volume":"139","author":"AE Frost","year":"2011","unstructured":"Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011;139(1):128\u201337.","journal-title":"Chest"},{"issue":"1","key":"2658_CR3","doi-asserted-by":"publisher","first-page":"204589402097730","DOI":"10.1177\/2045894020977300","volume":"11","author":"L Leber","year":"2021","unstructured":"Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021;11(1):2045894020977300. https:\/\/doi.org\/10.1177\/2045894020977300.","journal-title":"Pulm Circ"},{"issue":"2","key":"2658_CR4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1378\/chest.09-1140","volume":"137","author":"DB Badesch","year":"2010","unstructured":"Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376\u201387. https:\/\/doi.org\/10.1378\/chest.09-1140.","journal-title":"Chest"},{"issue":"123","key":"2658_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1183\/09059180.00008211","volume":"21","author":"MD McGoon","year":"2012","unstructured":"McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012;21(123):8\u201318. https:\/\/doi.org\/10.1183\/09059180.00008211.","journal-title":"Eur Respir Rev"},{"issue":"134","key":"2658_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1183\/09059180.00007814","volume":"23","author":"MM Hoeper","year":"2014","unstructured":"Hoeper MM, Simon R, Gibbs J. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev. 2014;23(134):450\u20137. https:\/\/doi.org\/10.1183\/09059180.00007814.","journal-title":"Eur Respir Rev."},{"issue":"2","key":"2658_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/1535370218824101","volume":"244","author":"E Zanatta","year":"2019","unstructured":"Zanatta E, Polito P, Famoso G, Larosa M, De Zorzi E, Scarpieri E, et al. Pulmonary arterial hypertension in connective tissue disorders: pathophysiology and treatment. Exp Biol Med (Maywood). 2019;244(2):120\u201331. https:\/\/doi.org\/10.1177\/1535370218824101.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"2658_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.hfc.2012.04.001","volume":"8","author":"SC Mathai","year":"2012","unstructured":"Mathai SC, Hassoun PM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin. 2012;8(3):413\u201325. https:\/\/doi.org\/10.1016\/j.hfc.2012.04.001.","journal-title":"Heart Fail Clin"},{"issue":"6","key":"2658_CR9","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1378\/chest.10-0260","volume":"138","author":"L Chung","year":"2010","unstructured":"Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138(6):1383\u201394. https:\/\/doi.org\/10.1378\/chest.10-0260.","journal-title":"Chest"},{"issue":"2","key":"2658_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/annrheumdis-2011-200265","volume":"71","author":"PJ Clements","year":"2012","unstructured":"Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, et al. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis. 2012;71(2):249\u201352. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200265.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2658_CR11","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1002\/art.22069","volume":"54","author":"MR Fisher","year":"2006","unstructured":"Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006;54(9):3043\u201350. https:\/\/doi.org\/10.1002\/art.22069.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2658_CR12","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1136\/annrheumdis-2012-202489","volume":"72","author":"D Launay","year":"2013","unstructured":"Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis. 2013;72(12):1940\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202489.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2658_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.chest.2017.02.010","volume":"152","author":"S Ramjug","year":"2017","unstructured":"Ramjug S, Hussain N, Hurdman J, Billings C, Charalampopoulos A, Elliot CA, et al. Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes. Chest. 2017;152(1):92\u2013102. https:\/\/doi.org\/10.1016\/j.chest.2017.02.010.","journal-title":"Chest"},{"key":"2658_CR14","doi-asserted-by":"crossref","unstructured":"Gaine S, Escribano P, Muller A, Klement R, S\u00f6derberg S, Lange T. Selexipag experience in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): real-world experience from EXPOSURE. C105 Civic Center Pulmonary Vascular Disease. American Thoracic Society; 2022. p. A4914-A.","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A4914"},{"issue":"4","key":"2658_CR15","doi-asserted-by":"publisher","first-page":"A2187","DOI":"10.1016\/j.chest.2020.08.1875","volume":"158","author":"K Chin","year":"2020","unstructured":"Chin K, Chakinala M, Hemnes A, Farber H, McLaughlin V, Kim N, et al. Real-world data for selixipag in patients with connective tissue disease-associated pulmonary arterial hypertension: a SPHERE (selexipag: the users drug reigistry) analysis. Chest. 2020;158(4):A2187\u201390.","journal-title":"Chest"},{"key":"2658_CR16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00673-2020","author":"O Sitbon","year":"2020","unstructured":"Sitbon O, Cottin V, Canuet M, Clerson P, Gressin V, Perchenet L, et al. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.00673-2020.","journal-title":"Eur Respir J."},{"issue":"9","key":"2658_CR17","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Galie","year":"2015","unstructured":"Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1413687.","journal-title":"N Engl J Med"},{"issue":"9","key":"2658_CR18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1213917.","journal-title":"N Engl J Med"},{"issue":"12","key":"2658_CR19","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.cjca.2016.03.004","volume":"32","author":"BD Fox","year":"2016","unstructured":"Fox BD, Shtraichman O, Langleben D, Shimony A, Kramer MR. Combination therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Can J Cardiol. 2016;32(12):1520\u201330. https:\/\/doi.org\/10.1016\/j.cjca.2016.03.004.","journal-title":"Can J Cardiol"},{"issue":"4","key":"2658_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","volume":"4","author":"AC Lajoie","year":"2016","unstructured":"Lajoie AC, Lauziere G, Lega JC, Lacasse Y, Martin S, Simard S, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4(4):291\u2013305. https:\/\/doi.org\/10.1016\/S2213-2600(16)00027-8.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"2658_CR21","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","volume":"76","author":"JG Coghlan","year":"2017","unstructured":"Coghlan JG, Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017;76(7):1219\u201327. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210236.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2658_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.41669","volume":"73","author":"D Khanna","year":"2021","unstructured":"Khanna D, Zhao C, Saggar R, Mathai SC, Chung L, Coghlan JG, et al. Long-term outcomes in patients with connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era: meta-analyses of randomized, controlled trials and observational registries. Arthritis Rheumatol. 2021;73(5):837\u201347. https:\/\/doi.org\/10.1002\/art.41669.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"2658_CR23","doi-asserted-by":"publisher","first-page":"e029024","DOI":"10.1161\/JAHA.122.029024","volume":"12","author":"BA Maron","year":"2023","unstructured":"Maron BA. Revised definition of pulmonary hypertension and approach to management: a clinical primer. J Am Heart Assoc. 2023;12(8):e029024. https:\/\/doi.org\/10.1161\/JAHA.122.029024.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2658_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","volume":"155","author":"JR Klinger","year":"2019","unstructured":"Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565\u201386. https:\/\/doi.org\/10.1016\/j.chest.2018.11.030.","journal-title":"Chest"},{"key":"2658_CR25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2020 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.00879-2022.","journal-title":"Eur Respir J."},{"key":"2658_CR26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02493-2016","author":"S Gaine","year":"2017","unstructured":"Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galie N, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017. https:\/\/doi.org\/10.1183\/13993003.02493-2016.","journal-title":"Eur Respir J."},{"issue":"1","key":"2658_CR27","doi-asserted-by":"publisher","first-page":"204589401881629","DOI":"10.1177\/2045894018816294","volume":"9","author":"S Studer","year":"2019","unstructured":"Studer S, Hull M, Pruett J, Koep E, Tsang Y, Drake W 3rd. Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database. Pulm Circ. 2019;9(1):2045894018816294. https:\/\/doi.org\/10.1177\/2045894018816294.","journal-title":"Pulm Circ"},{"key":"2658_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13804","author":"M Wissmuller","year":"2022","unstructured":"Wissmuller M, Xanthouli P, Benjamin N, Grunig E, Richter MJ, Gall H, et al. Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres. ESC Heart Fail. 2022. https:\/\/doi.org\/10.1002\/ehf2.13804.","journal-title":"ESC Heart Fail"},{"key":"2658_CR29","doi-asserted-by":"crossref","unstructured":"Lammi MR, Chin K, Kim NH, McLaughlin VV, Zamanian R, Flynn M, et al. Real-world mono-, double and triple combination treatment patterns with macitentan in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): evidence from the combined OPUS\/OrPHeUS dataset. B27 Up-To-Date PAH Assessment and Management. American Thoracic Society; 2020. p. A2914-A.","DOI":"10.1164\/ajrccm-conference.2020.201.1_MeetingAbstracts.A2914"},{"issue":"2","key":"2658_CR30","doi-asserted-by":"publisher","first-page":"e12218","DOI":"10.1002\/pul2.12218","volume":"13","author":"Y Tsang","year":"2023","unstructured":"Tsang Y, Panjabi S, Funtanilla V, Germack HD, Gauthier-Loiselle M, Manceur AM, et al. Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD). Pulm Circ. 2023;13(2):e12218. https:\/\/doi.org\/10.1002\/pul2.12218.","journal-title":"Pulm Circ."},{"key":"2658_CR31","doi-asserted-by":"crossref","unstructured":"Ravichandran A, Zamanian R, Channick R, Chin K, Kim N, Martinez E, et al. Epidemiology and treatment patterns of pulmonary arterial hypertension (PAH) patients across US regions using real-world data from OPUS\/OrPHeUS. TP86 while my guitar gently weeps-novel epidemiologic studies in pulmonary vascular disease. American Thoracic Society; 2021. p. A3702-A.","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A3702"},{"issue":"4","key":"2658_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.healun.2021.01.006","volume":"40","author":"NH Kim","year":"2021","unstructured":"Kim NH, Hemnes AR, Chakinala MM, Highland KB, Chin KM, McLaughlin V, et al. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. J Heart Lung Transplant. 2021;40(4):279\u201388. https:\/\/doi.org\/10.1016\/j.healun.2021.01.006.","journal-title":"J Heart Lung Transplant"},{"key":"2658_CR33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02148-2018","author":"N Galie","year":"2019","unstructured":"Galie N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th world symposium on pulmonary hypertension. Eur Respir J. 2019. https:\/\/doi.org\/10.1183\/13993003.02148-2018.","journal-title":"Eur Respir J."},{"issue":"1","key":"2658_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Galie","year":"2016","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67\u2013119. https:\/\/doi.org\/10.1093\/eurheartj\/ehv317.","journal-title":"Eur Heart J"},{"issue":"9","key":"2658_CR35","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamacardio.2016.4471","volume":"1","author":"BA Maron","year":"2016","unstructured":"Maron BA, Galie N. Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: a review. JAMA Cardiol. 2016;1(9):1056\u201365. https:\/\/doi.org\/10.1001\/jamacardio.2016.4471.","journal-title":"JAMA Cardiol"},{"key":"2658_CR36","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2147\/CEOR.S119117","volume":"9","author":"CD Burger","year":"2017","unstructured":"Burger CD, Ghandour M, Padmanabhan Menon D, Helmi H, Benza RL. Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. Clinicoecon Outcomes Res. 2017;9:731\u20139. https:\/\/doi.org\/10.2147\/CEOR.S119117.","journal-title":"Clinicoecon Outcomes Res"},{"key":"2658_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/diseases8020022","author":"SA Helgeson","year":"2020","unstructured":"Helgeson SA, Menon D, Helmi H, Vadlamudi C, Moss JE, Zeiger TK, et al. Psychosocial and financial burden of therapy in USA patients with pulmonary arterial hypertension. Diseases. 2020. https:\/\/doi.org\/10.3390\/diseases8020022.","journal-title":"Diseases"},{"key":"2658_CR38","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1186\/s12913-014-0676-0","volume":"14","author":"M Sikirica","year":"2014","unstructured":"Sikirica M, Iorga SR, Bancroft T, Potash J. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Serv Res. 2014;14:676. https:\/\/doi.org\/10.1186\/s12913-014-0676-0.","journal-title":"BMC Health Serv Res"},{"key":"2658_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-2466-12-75","volume":"12","author":"A Berger","year":"2012","unstructured":"Berger A, Edelsberg J, Teal S, Mychaskiw MA, Oster G. Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study. BMC Pulm Med. 2012;12:75. https:\/\/doi.org\/10.1186\/1471-2466-12-75.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"2658_CR40","doi-asserted-by":"publisher","first-page":"A49","DOI":"10.1016\/j.jval.2016.03.124","volume":"19","author":"CD Burger","year":"2016","unstructured":"Burger CD, Ozbay B, Riehle E, Montejano LB, White RJ. Health care resource utilization and cost among pulmonary arterial hypertension patients before and after sequential combination therapy initiation. Value Health. 2016;19(3):A49\u201350.","journal-title":"Value Health"},{"issue":"4","key":"2658_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40256-018-0272-5","volume":"18","author":"M Burks","year":"2018","unstructured":"Burks M, Stickel S, Galie N. Pulmonary arterial hypertension: combination therapy in practice. Am J Cardiovasc Drugs. 2018;18(4):249\u201357. https:\/\/doi.org\/10.1007\/s40256-018-0272-5.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"2658_CR42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.chest.2021.01.066","volume":"160","author":"S Gaine","year":"2021","unstructured":"Gaine S, Sitbon O, Channick RN, Chin KM, Sauter R, Galie N, et al. Relationship between time from diagnosis and morbidity\/mortality in pulmonary arterial hypertension: results from the phase III GRIPHON study. Chest. 2021;160(1):277\u201386. https:\/\/doi.org\/10.1016\/j.chest.2021.01.066.","journal-title":"Chest"},{"issue":"1","key":"2658_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.chest.2021.02.009","volume":"160","author":"M Naranjo","year":"2021","unstructured":"Naranjo M, Hassoun PM. Time is of the essence in PAH therapy. Chest. 2021;160(1):25\u20136. https:\/\/doi.org\/10.1016\/j.chest.2021.02.009.","journal-title":"Chest"},{"issue":"3 Suppl","key":"2658_CR44","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.37765\/ajmc.2021.88611","volume":"27","author":"DS Burgoyne","year":"2021","unstructured":"Burgoyne DS. Reducing economic burden and improving quality of life in pulmonary arterial hypertension. Am J Manag Care. 2021;27(3 Suppl):S53\u20138. https:\/\/doi.org\/10.37765\/ajmc.2021.88611.","journal-title":"Am J Manag Care"},{"issue":"12","key":"2658_CR45","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1002\/art.38172","volume":"65","author":"D Khanna","year":"2013","unstructured":"Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, et al. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum. 2013;65(12):3194\u2013201. https:\/\/doi.org\/10.1002\/art.38172.","journal-title":"Arthritis Rheum"},{"key":"2658_CR46","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01889-2018","author":"N Galie","year":"2019","unstructured":"Galie N, Channick RN, Frantz RP, Grunig E, Jing ZC, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019. https:\/\/doi.org\/10.1183\/13993003.01889-2018.","journal-title":"Eur Respir J."},{"issue":"2","key":"2658_CR47","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1161\/CIRCOUTCOMES.117.003973","volume":"11","author":"DT Wijeratne","year":"2018","unstructured":"Wijeratne DT, Lajkosz K, Brogly SB, Lougheed MD, Jiang L, Housin A, et al. Increasing incidence and prevalence of World Health Organization groups 1 to 4 pulmonary hypertension: a population-based cohort study in Ontario, Canada. Circ Cardiovasc Qual Outcomes. 2018;11(2):973. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.117.003973.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2658_CR48","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139.","journal-title":"Med Care"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02658-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02658-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02658-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T10:41:58Z","timestamp":1697020918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02658-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2658"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02658-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"assertion":[{"value":"19 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yuen Tsang, Sumeet Panjabi, Vienica Funtanilla, and Hayley D Germack are employees of Janssen Scientific Affairs, LLC and may own stock\/stock options.\u00a0Marjolaine Gauthier-Loiselle, Aameu M Manceur, Martin Cloutier, and Patrick Lefebvre are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Janssen Scientific Affairs, LLC, which funded the development and conduct of this study and manuscript. Therese Sargent has received consultancy fees from Janssen Scientific Affairs, LLC. Finally, we note that the study sponsor, Janssen Scientific Affairs, LLC, is a manufacturer of therapies for PH\/PAH, including bosentan, epoprostenol, iloprost, macitentan, and selexipag.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data were de-identified and comply with the patient requirements of the HIPAA of 1996; therefore, no review by an institutional review board was required per Title 45 of CFR, Part 46.101(b)(4) (). The present study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}}]}}